About the Authors

William Pao, Theresa Y Wang, Harold E Varmus
Program in Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

William Pao, Gregory J Riely, Vincent A Miller, Mark G Kris
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

Qiulu Pan, Marc Ladanyi, Maureen F Zakowski
Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

Robert T Heelan
Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

Corresponding Author

paow@mskcc.org

Competing Interests

VAM has received research funding from Genentech (co-developer of erlotinib). He has received honoraria from AstraZeneca (maker of gefitinib) for consultancy. MGK has received research funding from AstraZeneca and research funding and consulting fees from Genentech and has represented AstraZeneca before the US Food and Drug Administration. WP, VAM, MFZ, and HEV, represented by the Sloan-Kettering Institute for Cancer Research, filed on June 1, 2004, a provisional patent application entitled “Use of mutations in EGFR kinase as an indicator of therapeutic efficacy of erlotinib in the treatment of NSCLC,” serial number 60/576,275. HEV is Co-founder and Chair of the Board of Directors of the Public Library of Science.

Author Contributions

WP and HEV designed the study. QP and ML designed and performed more sensitive methods to detect EGFR mutations. WP, TYW, GJR, VAM, MFZ, MGK, and RTH acquired and analyzed the data. WP, TYW, and HEV contributed to writing the paper.